While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

BridgeBio Cardiorenal chief medical officer Dr Jonathan Fox stated: “The EU approval of acoramidis is a significant ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

(RTTNews) - BridgeBio Pharma, Inc. (BBIO) announced on Tuesday that the European Commission has granted marketing authorization for BEYONTTRA or acoramidis, the first near-complete TTR stabilizer ...

Pharma announced the European Commission has granted marketing authorization in the European Union for acoramidis, under the ...

ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Bayer will be responsible for all commercial activity for acoramidis ...

The study involved 632 subjects with symptomatic ATTR-CM and met its primary clinical endpoints at month 30. It showed a significant decrease in cardiovascular-related hospitalisation, improved ...

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date In as few as 3 ...